While inhibiting the excessive activation of the JAK-STAT pathway, whether directly hindering tumor proliferation or modulating tumor immunity, can offer therapeutic benefits, the broader utilization of JAK inhibitors in cancer treatment has faced challenges due to their immunosuppressive characteristics [36]. The gene discussed is SOAT1; the disease is cancer.